AGENUS INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
AGENUS INC (AGEN) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $582.19 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-07
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $582.19K.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $1.21M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $753.14K.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $2.43M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value |
|---|---|
| 2026-06-30 | $582.19K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $1.21M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $753.14K 10-K · filed 2026-03-16 |
| 2025-09-30 | $2.43M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $4.04M 10-Q · filed 2025-08-11 |
| 2024-09-30 | $111.00 10-Q · filed 2024-11-12 |
| 2024-06-30 | $5.57M 10-Q · filed 2024-08-08 |
| 2023-12-31 | $28.10K 10-K · filed 2024-03-14 |
| 2023-06-30 | $53.75K 10-Q · filed 2023-08-08 |
| 2022-12-31 | $1.17M 10-K · filed 2023-03-16 |
| 2022-09-30 | $464.89K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $337.40K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.20M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $6.31M 10-K · filed 2022-03-01 |
| 2021-09-30 | $54.32M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $63.68M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $3.09M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $7.09M 10-K · filed 2021-03-16 |
| 2020-09-30 | $16.18M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $16.02M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $1.57M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $19.78M 10-K · filed 2020-03-16 |
| 2019-09-30 | $2.91M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $5.96M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $2.71M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $1.32M 10-K · filed 2019-03-18 |
| 2018-09-30 | $25.09K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $357.00 10-Q · filed 2018-08-09 |
| 2018-03-31 | $10.88M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $707.66K 10-K · filed 2018-03-16 |
| 2017-09-30 | $5.21M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $3.32M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $2.27M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $3.75M 10-K · filed 2017-03-16 |
| 2016-09-30 | $32.84M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $3.58M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $3.97M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $5.58M 10-K · filed 2016-03-15 |
| 2015-09-30 | $5.97M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $32.90M 10-Q · filed 2015-08-03 |
| 2015-03-31 | $8.84M 10-Q · filed 2015-05-01 |
| 2014-12-31 | $3.79M 10-K · filed 2015-03-16 |
| 2014-09-30 | $492.64K 10-Q · filed 2014-10-31 |
| 2014-06-30 | $884.69K 10-Q · filed 2014-08-01 |
| 2014-03-31 | $212.66K 10-Q · filed 2014-05-09 |
| 2013-12-31 | $2.32K 10-K · filed 2014-03-07 |
| 2013-09-30 | $23.28K 10-Q · filed 2013-11-08 |
| 2013-06-30 | $324.42K 10-Q · filed 2013-08-09 |
| 2013-03-31 | $220.01K 10-Q · filed 2013-05-10 |
| 2012-12-31 | $305.83K 10-K · filed 2013-03-18 |
| 2012-09-30 | $540.03K 10-Q · filed 2012-11-07 |
| 2012-06-30 | $959.18K 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |